Weight & Metabolic

Fatty Liver: Symptoms, Grades, and How It Reverses

Fatty liver, or hepatic steatosis, means excess fat has built up inside liver cells. Around 38.6% of Indian adults have it, and most of them feel nothing at all. The grade printed on your ultrasound report measures how much fat sits in the liver. It predicts your future far less well than a second number that most reports leave out.

What is fatty liver? Copy link

Fatty liver is fat stored inside liver cells. A normal liver holds a small amount. Steatosis is generally defined as fat in at least 5% of hepatocytes on histology, or the equivalent finding by validated imaging criteria; imaging estimates how much fat is there; it does not count cells. India's 2024 operational guideline separately describes fatty liver as fat exceeding 5% of liver weight.

You will see two names for the common form. The older one is NAFLD, which you will see written as both non-alcoholic fatty liver disease and nonalcoholic fatty liver disease. In 2023 an international consensus group replaced it with MASLD, metabolic dysfunction-associated steatotic liver disease, to put the cause in the name. The definition is precise: steatosis plus at least one of five cardiometabolic risk factors is enough. Those five are a raised BMI or waist circumference, with a BMI of 23 used for Asian populations; raised fasting glucose, HbA1c or treated type 2 diabetes; blood pressure of 130/85 or above, or treatment for it; triglycerides of 150 mg/dL or above, or treatment; and low HDL cholesterol, or treatment. One is enough. You do not need the whole set. Other causes can coexist with metabolic disease rather than sitting apart from it. Alcohol, some medicines such as steroids and tamoxifen, viral hepatitis and a few inherited conditions can all change the classification and the management. Metabolic dysfunction with moderate alcohol intake, for example, is classified as MetALD: roughly 140 to 350 g of alcohol a week in women and 210 to 420 g a week in men. Above those upper thresholds, alcohol-related liver disease becomes the dominant classification.

Doctors describe it as a spectrum. Simple steatosis is fat without inflammation. MASH, previously called NASH, is fat plus inflammation and cell injury. Repeated injury lays down scar tissue, which is fibrosis, and enough of it over enough years becomes cirrhosis. Indian government guidance sets out the same four steps.

What do grade 1, grade 2 and grade 3 fatty liver mean? Copy link

Fatty liver ultrasound grading is a three-step scale, and it describes the amount of fat visible on the scan. It does not describe damage.

Those grades come from an ultrasound, and they describe brightness. Fat scatters sound, so a fatty liver looks brighter on the screen than the kidney next to it, and structures deeper in start to fade.

Radiologists read three things at once. How bright the liver looks against the right kidney beside it. Whether the walls of the portal veins running through it still stand out. Whether the diaphragm behind the liver is still visible, or has been washed out by the fat sitting in front of it.

This is an eye judgement, so it moves between operators. In a radiology review of the imaging methods, two readers grading the same liver agreed at a kappa of 0.43, which counts as fair agreement on the standard scale, and the same review cites a sensitivity of 73.3% for picking up the mildest degrees of steatosis in one comparison study. Your grade 2 could be read as grade 1 on another machine in another clinic, which is a useful thing to hold in mind before you treat the number as a verdict on your health.

A FibroScan gives a measured number instead. Its CAP score has cutoffs at 248, 268 and 280 dB/m, and those cutoffs sort a liver into grade S1, S2 or S3. The Indian guideline's table pairs those grades with the share of liver cells holding fat: 11% to 33% for S1, 34% to 66% for S2, and 67% or more for S3. Two wrinkles are worth carrying. A CAP number is a threshold tool, so it sorts you into a band and does not convert into an exact percentage of your liver. And the guideline's table starts S1 at 11%, while the 5% figure quoted everywhere is the separate question of when a liver counts as fatty at all. Different measurement systems, different floors.

If your report also gives a liver size in centimetres, read it separately. A fatty liver is often enlarged, but Indian guidance states plainly that fatty liver can be present with a completely normal liver size.

Is grade 2 fatty liver dangerous? Copy link

On its own, the grade does not answer that. What carries most of the risk of illness and death in fatty liver is how much scarring the liver has laid down, and ultrasound grade does not measure scarring.

A Swedish cohort followed 229 people with biopsy-proven fatty liver for up to 33 years. Their inflammation score did not predict overall mortality. Fibrosis stage did, and people at stage 3 or 4 had roughly three times the death rate whatever their inflammation score. A separate 2015 analysis reached the same place from different data: fibrosis, and no other feature seen under the microscope, tracked long-term outcomes.

The size of the gap is worth stating precisely. Pooling 14 studies and 17,301 people with biopsy-confirmed disease, all-cause mortality at ten years was 7.7% for fibrosis stages 0 to 2, and 41.5% at stage 4 cirrhosis. At five years the same split was 3.3% against 20.6%.

Most people with a fatty liver never move along that line at all, and the ones who do usually take decades over it. A meta-analysis of 411 people who had two liver biopsies at least a year apart found that scarring advanced by one stage roughly every 14.3 years in simple fatty liver and every 7.1 years once inflammation was present. Over that same follow-up, 33.6% progressed, 43.1% stayed where they were, and 22.3% improved. Scarring moves in both directions.

India runs a national screening pathway for this, and it is built around the second column. Under the national non-communicable disease programme, someone found to have fatty liver gets a complete blood count and a liver function test, and those results are fed into a FIB-4 score. Below 1.30 is low risk for advanced scarring. Above 2.67 is high risk and needs a specialist. Anything in between goes for a FibroScan, where a stiffness above 7.9 kPa raises concern for significant fibrosis under this pathway. The ultrasound grade that worries people appears nowhere in that algorithm, which is the clearest signal available that the profession treats it as a finding to be explained and not as a score to be ranked.

Two limits on FIB-4 are worth knowing before you read your own. It was built for middle age and performs poorly under about 35. And over 65 the lower cutoff is commonly raised to 2.0, because age is one of the inputs and it drags the score up on its own.

What are the symptoms of fatty liver? Copy link

For most people, none. That is the difficulty with it: the signs of a fatty liver are usually absent until the disease is well along. Fatty liver is usually found by accident, on a scan done for something else or through liver enzymes that came back raised on a routine panel.

Where symptoms do appear, Indian government guidance lists fatigue, a general feeling of being unwell, and discomfort under the right ribs. All three are common, vague, and caused by many other things. Sharp or persistent pain there deserves its own assessment.

Why do so many Indians get fatty liver, including thin people? Copy link

A meta-analysis of the published Indian literature put adult prevalence at 38.6%, with a confidence interval of 32% to 45.5%. In average-risk groups it was 28.1%. In high-risk groups it was 52.8%. Among Indian children, 35.4%.

The thresholds used to flag risk here are lower than the international ones, because South Asian bodies run into metabolic trouble at lower weights. India's programme treats a BMI of 23 or above as raised risk, and a waist over 90 cm in men or 80 cm in women. Those are the same Indian BMI cut-offs used across the rest of metabolic medicine here, and a waist measurement often flags the risk before the scale does.

Fatty liver rarely arrives alone. It is filed under weight and metabolic health because that is where its causes sit. Indian guidance puts its prevalence at 60% to 90% in people with obesity, around 70% in type 2 diabetes, and 53% in metabolic syndrome. Insulin resistance sits underneath most of it, and visceral fat drains directly into the liver through the portal vein.

Thin people get it too. The national guideline writes a separate lifestyle target for lean patients, and a programme written for a country of 1.4 billion does not carve out a special case for a group its authors expect to see once a year. One caution about the numbers above: the authors of that meta-analysis noted their data came mostly from hospital studies, covered 15 of 35 states and union territories, and contained almost nothing on lean disease specifically. Treat 38.6% as the best available estimate of a moving target.

How do you test for fatty liver? Copy link

How to check for fatty liver, in routine Indian practice, usually starts with an abdominal ultrasound, because it is inexpensive and widely available. It can identify steatosis and grade it by eye, though milder disease can be missed.

Blood tests come next, and one point catches people out: SGPT and SGOT can sit in the normal range while the liver is visibly fatty. Normal enzymes do not rule fatty liver out, raised enzymes do not tell you how much scarring there is, and a great many people have been reassured by one result or frightened by the other on the strength of a number that answers neither question.

Ask for the set that lets someone calculate a FIB-4. A complete blood count and a liver function test cover it, because the score is built from your age, the two enzymes and the platelet count. Ask for fasting glucose or HbA1c and a lipid profile in the same visit, because they change what the finding means. A FibroScan is the next step when the FIB-4 lands in the middle.

Can fatty liver be reversed, and how long does it take? Copy link

Liver fat can fall substantially, and sometimes clear, when the underlying metabolic drivers improve. Weight loss is the lever with the strongest evidence behind it. Even scarring improves in a meaningful share of people. What becomes hard to undo is established cirrhosis, where some reversal is possible when the cause is controlled but the rebuilt architecture of the organ often stays.

The clearest data come from a Cuban trial that put 293 adults with biopsy-proven steatohepatitis through a supervised lifestyle programme for 52 weeks and re-biopsied them. Among those who lost 5% of body weight or more, the inflamed form resolved in 58%. Among those who lost 10% or more, it resolved in 90%, and scarring improved in 45%.

Now the part that rarely gets quoted. Only 30% of that trial reached 5% weight loss at all, with fortnightly follow-up and a research team behind them. The probability of histologic improvement rose sharply with the amount of weight lost. Getting to those amounts is the hard part, and any plan that skips past how you will actually lose the weight, and keep it off past the twelfth week, is a plan that has skipped the only part that was ever going to be hard.

Indian guidance sets the targets by where you are. At least 5% for fat alone, and 7% to 10% where scarring has started. For lean patients the guideline says two different things in two places, and both are worth knowing rather than averaging: one section sets a 3% to 5% weight reduction in lean or normal-weight disease, while the next describes lean management as maintaining current weight on a nutrient-dense diet. Ask your doctor which applies to you. Exercise for fatty liver is specified too: 150 minutes a week of moderate aerobic activity plus strength work twice a week. Alcohol is to be avoided completely.

On speed, there is no single timeline. Liver fat starts falling within weeks once you eat less and weigh less. In a small study of 18 people with fatty liver, two weeks of dieting and about 4.3% weight loss cut liver triglyceride by roughly 42%, measured on scanning rather than biopsy. So people searching how to reduce fatty liver quickly, or how to reduce fatty liver in 14 days, are not chasing nothing. What two weeks does not buy is the clearing of inflammation or the reversal of scarring, and those are the outcomes measured in the twelve-month trial above. For people who cannot reach these targets on their own, supervised weight-loss treatment is a reasonable conversation to have with a doctor.

What should you eat for fatty liver? Copy link

The pattern matters more than any single food, which is the opposite of how most fatty-liver eating advice is organised, and it is the reason no list of permitted fruits will do the work on its own. Indian guidance asks for complex carbohydrates over refined ones, more fiber from whole grains, vegetables, fruit and legumes, less saturated fat, no trans fat, and portions sized to your actual energy needs. It names millets specifically, which is the sort of detail that makes a national guideline more useful than an imported one, because the substitution it is asking you to make is one you can actually buy.

The foods to avoid with fatty liver start with added sugar and sugary or aerated drinks. Excess free sugar, particularly from sweetened drinks, pushes the liver to make more fat of its own, and it delivers a lot of energy with no fiber and little fullness in return. Whole fruit fits comfortably inside the fiber advice; fruit juice belongs with the sugary drinks.

Coffee has better evidence than most things marketed for the liver, and it is more modest than the headlines suggest. A 2021 meta-analysis found no link between coffee drinking and whether people developed fatty liver, but coffee drinkers who already had it had about 35% lower odds of significant fibrosis. Those were observational studies, so coffee earns a place in your day without earning the word treatment.

Do ayurvedic medicines and liver tonics work for fatty liver? Copy link

Ayurvedic treatment for fatty liver, homeopathic medicine for fatty liver, and the liver tonics sold over the counter share one thing. No product in these categories appears in India's national guideline or in the specialist treatment literature as a treatment for fatty liver, and some of them carry a measurable risk to the organ you are trying to protect.

The Indian Network of Drug-Induced Liver Injury looked at 1,288 cases of drug-caused liver injury across the country. Traditional and complementary medicines, covering Ayurveda, Unani, Siddha and homeopathy, accounted for 14% of them, behind anti-tuberculosis drugs at 46%. Registry mortality across all causes of drug-induced injury was 12%.

The mechanism is mundane. These preparations are often multi-ingredient with undeclared constituents, so when something goes wrong nobody can say which extract in the bottle caused it. That is also why the injury is easy to miss: nothing on the label points at a suspect.

Naturally, most people who take them come to no harm. If you are taking the best-selling liver tonic on the shelf, a giloy or bhumi amla preparation, or any herbal capsule, tell your doctor the exact product name and ask for liver enzymes to be repeated while you are on it. If those enzymes rise, or you develop jaundice, dark urine, severe nausea or unusual tiredness, contact a doctor promptly and do not keep taking a non-essential supplement while the cause is being worked out.

Which medicines are approved for fatty liver in India? Copy link

If you are searching for a fatty liver tablet name, India now has two routes, and one of them opened in 2026.

Saroglitazar 4 mg, developed in India and sold as Lipaglyn and other brands, carries two separate Indian indications. The Drugs Controller General approved it for non-cirrhotic NASH in March 2020, and then in December 2020 for fatty liver disease occurring alongside one of obesity, type 2 diabetes, dyslipidaemia or metabolic syndrome. Zydus describes the 2020 NASH clearance as the first national approval of a drug specifically for non-cirrhotic NASH anywhere in the world.

In July 2026 the Central Drugs Standard Control Organisation approved a new indication for Wegovy, semaglutide 2.4 mg, covering adults with non-cirrhotic MASH and moderate to advanced liver fibrosis, alongside a reduced-calorie diet and more physical activity. The CDSCO expert committee had recommended it in April 2026 for fibrosis stages F2 to F3. That makes it the first GLP-1 medicine with an Indian MASH indication.

The approval rested on a phase 3 trial in adults with MASH and stage 2 or 3 fibrosis. At 72 weeks, 62.9% on weekly semaglutide 2.4 mg had the inflamed form resolve without worsening fibrosis, against 34.3% on placebo. Scarring improved in 36.8% against 22.4%.

One thing to be careful about. The MASH indication belongs to the approved Wegovy product, and another semaglutide brand or generic does not inherit it. Several GLP-1 medicines are sold here, so ask your prescriber what the specific product in front of you is licensed for.

A note on the guideline, because you may read it and be confused. India's 2024 national operational guideline states that no specific medicine is approved as a standard treatment for fatty liver. That sentence describes a programmatic position on what belongs in routine first-line care across a national screening service. It is not a regulatory inventory. Saroglitazar held its indications well before 2024, and Wegovy's was added in 2026.

Vitamin E and pioglitazone are used off licence in selected patients by specialists. Neither belongs in a self-prescribed regimen, both need monitoring, and the decision to use them turns on a fibrosis assessment you will not have done at home.

When to see a doctor Copy link

Book an appointment if an ultrasound has reported fatty liver of any grade and nobody has worked out with you why it is there. Book one if your liver enzymes came back raised and were never repeated. Ask whether a FIB-4 has been calculated. If it has not, ask for it.

Go sooner if you have type 2 diabetes, since fatty liver is present in roughly seven in ten people who do, and diabetes raises the odds that scarring is already underway. Yellow eyes or a swelling abdomen need prompt assessment. Vomiting blood, black stools, new confusion or fainting need emergency care.